

Viviana Bazan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7630958/publications.pdf>

Version: 2024-02-01

60
papers

2,023
citations

293460

24
h-index

286692

43
g-index

61
all docs

61
docs citations

61
times ranked

3889
citing authors

#	ARTICLE	IF	CITATIONS
1	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103597.	2.0	19
2	BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103626.	2.0	6
3	Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength. <i>Frontiers in Oncology</i> , 2022, 12, 827822.	1.3	6
4	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	1.4	0
5	MUTYH-associated tumor syndrome: The other face of MAP. <i>Oncogene</i> , 2022, 41, 2531-2539.	2.6	10
6	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	1.4	3
7	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. <i>Cancers</i> , 2021, 13, 993.	1.7	14
8	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. <i>Cancers</i> , 2021, 13, 2118.	1.7	23
9	Advanced breast cancer at presentation (ABC-p) in octogenarian women (OW): Specific elderly-devoted risk tests (SEDRT) (CARG+CRASH) as new tools to prevent serious/irreversible adverse reactions (AR) in frail patients. <i>Journal of Clinical Oncology</i> , 2021, 39, e12510-e12510.	0.8	1
10	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	1.3	14
11	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	2.0	10
12	POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. <i>Oncogene</i> , 2021, 40, 5893-5901.	2.6	34
13	Biomarkers. <i>UNIPA Springer Series</i> , 2021, , 43-64.	0.1	0
14	A Lymphocyte MicroRNA Signature as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. <i>Cancers</i> , 2020, 12, 3396.	1.7	41
15	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolmmunology</i> , 2020, 9, 1832348.	2.1	55
16	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. <i>Cancers</i> , 2020, 12, 2415.	1.7	40
17	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 474.	1.7	51
18	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily) – Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. <i>Cancers</i> , 2020, 12, 1158.	1.7	30

#	ARTICLE	IF	CITATIONS
19	<i>BRCA1/2</i> pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097532.	1.4	34
20	Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC). <i>Journal of Clinical Oncology</i> , 2020, 38, e16093-e16093.	0.8	1
21	Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019, 18, 100252.	1.0	23
22	How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 68-75.	2.0	4
23	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	1.7	4
24	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80
25	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984887.	1.4	30
26	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 485-496.	1.0	10
27	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	13
28	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. <i>Cellular Immunology</i> , 2019, 343, 103753.	1.4	187
29	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile. <i>Journal of Clinical Oncology</i> , 2019, 37, e16109-e16109.	0.8	0
30	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1197-1209.	1.0	11
31	Circular RNA in Exosomes. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1087, 109-117.	0.8	139
32	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 13379.	1.6	66
33	EGFR inhibition in NSCLC: New findings and opened questions?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 126-135.	2.0	22
34	The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 227-233.	2.0	15
35	Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. <i>PPAR Research</i> , 2017, 2017, 1-15.	1.1	119
36	Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin. <i>Oncotarget</i> , 2017, 8, 71924-71932.	0.8	26

#	ARTICLE	IF	CITATIONS
37	Effects of erybuline/capecitabine (EC) treatment in very elderly women (VEW) with MBC.. Journal of Clinical Oncology, 2017, 35, e12508-e12508.	0.8	0
38	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget, 2016, 7, 47821-47830.	0.8	36
39	Dietary restriction: could it be considered as speed bump on tumor progression road?. Tumor Biology, 2016, 37, 7109-7118.	0.8	24
40	Non-coding RNAs Functioning in Colorectal Cancer Stem Cells. Advances in Experimental Medicine and Biology, 2016, 937, 93-108.	0.8	24
41	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. Critical Reviews in Oncology/Hematology, 2016, 107, 20-32.	2.0	31
42	Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. Advances in Experimental Medicine and Biology, 2016, 937, 207-228.	0.8	55
43	Nintedanib in NSCLC: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 188-197.	1.4	19
44	A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology, 2016, 37, 4263-4273.	0.8	18
45	Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 99, 150-157.	2.0	81
46	Absence of germlineCDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?. Cancer Biology and Therapy, 2016, 17, 83-90.	1.5	18
47	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget, 2016, 7, 60712-60722.	0.8	103
48	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget, 2016, 7, 21259-21271.	0.8	16
49	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget, 2016, 7, 19738-19747.	0.8	134
50	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. Oncotarget, 2016, 7, 29321-29332.	0.8	23
51	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, 3565-3565.	0.8	0
52	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. Analytical Cellular Pathology, 2015, 2015, 1-19.	0.7	80
53	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget, 2015, 6, 35589-35601.	0.8	57
54	Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).. Journal of Clinical Oncology, 2014, 32, e20513-e20513.	0.8	0

#	ARTICLE	IF	CITATIONS
55	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 505-517.	1.1	29
56	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	32
57	Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 67-70.	1.1	23
58	Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?*. <i>Journal of Cellular Physiology</i> , 2002, 191, 237-246.	2.0	18
59	Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2002, 192, 286-293.	2.0	32
60	DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma. <i>Cancer</i> , 2001, 92, 294-302.	2.0	23